الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 139 |  |  |
| | | from | 139 | | |
Abstract
The objective of this study was to assess the efficacy, safety, early clinical outcomes, and patient satisfaction following pelvic congestion syndrome (PCS) embolization in individuals with chronic pelvic discomfort who initially sought medical attention for lower limb venous insufficiency.
This study was conducted as a prospective clinical investigation with a cohort of 40 consecutive patients diagnosed with pelvic congestion syndrome. The present study was conducted in the Department of Vascular and Endovascular Surgery at Ain-Shams University and EL-MINIA University Hospitals in Egypt.
The main findings of the study revealed that:
The distribution of ages within the study population. The age range of the study population was between 20 and 40 years, with a mean ± standard deviation of 29.1 ± 5.1. The quantity of individuals within the age range of 20 to 30 years who are seeking medical treatment. The study population exhibited an age distribution in which 24 individuals, constituting 60% of the total sample, were seen.The study population consisted of 21 patients, accounting for 52.50%, who reported regular menstruation. The study sample consisted of 8 individuals (20%) who had a history of uniparous Obstetrics.The study population consisted of 15 patients, representing 37.50% of individuals with Vulva varices. The study population consisted of 7 patients, or 17.50% of the total population, who were diagnosed with Hemorrhoids. The study population consisted of 35 individuals, representing 87.50% of the total sample, who reported experiencing Dyspareunia. The study population consisted of 16 patients, representing 40% of the total sample, who experienced Dysurea. The study population consisted of 26 patients, or 65% of the total sample, who experienced symptoms of urgency. The study population included of 30 patients, representing 75% of individuals with Tender ovarian point.The study population included of 24 patients, accounting for 60%, who exhibited Competent Saphenous-femoral junction. The study population consisted of 38 patients (95%) who shown competence in the Saphenous-popliteal junction.The study population consisted of 18 patients (45%) who exhibited a Normal Greater saphenous vein. The study population consisted of 36 patients (90%) who had a Normal Short saphenous vein.The study population consisted of 40 patients, all of whom had Atypical LL varicosity. The study population consisted of 36 patients (90%) with the Ovarian vein as the targeted vein. The study sample exhibited a range of durations (min) from 20 to 69, with a mean ± standard deviation (SD) of 41.98 ± 12.46. Similarly, the pelvic lying baseline in the study population ranged from 1 to 1, with a mean ± SD of 1 ± 0. The occurrence of Pelvic Lying one month after the study was seen in the study population, with a range of 0 to 1. The mean value, represented as mean ± standard deviation (SD), was calculated to be 0.25 ± 0.44. The occurrence of Pelvic Lying, three months after the study, varied between 0 and 1 within the population under investigation, with a mean value of 0.15 ± 0.36. The pelvic lying measurements obtained six months after the study commenced varied between 0 and 1, with a mean value of 0.1 ± 0.3 (mean ± standard deviation). Similarly, the baseline pelvic standing measurements in the study group ranged from 3 to 6, with a mean value of 4.2 ± 0.76. The pelvic standing ability of the study population was seen to range from 1 to 3, with a mean value of 1.92 ± 0.42.The study population exhibited a range of 1 to 2 for pelvic standing 3 months after the intervention, with a mean value of 1.48 ± 0.51 (mean ± standard deviation). The study population exhibited a range of 1 to 2 for pelvic standing at the 6-month mark, with a mean value of 1.42 ± 0.5 (mean ± standard deviation). The study population exhibited a range of 1 to 2 in terms of pelvic standing 12 months after the initial assessment, with a mean value of 1.12 ± 0.33 (mean ± standard deviation).The leg lying baseline in the study population exhibited a range of 1 to 2, with a mean value of 1.08 ± 0.27. Similarly, the leg lying measurements taken one month later in the study population varied from 0 to 2, with a mean value of 1.02 ± 0.28. The leg lying measurements were recorded at three different time points in the study population. At 3 months, the range of leg lying scores varied from 0 to 1, with a mean of 0.98 and a standard deviation of 0.16. At 6 months, the range of leg lying scores also varied from 0 to 1, with a mean of 0.92 and a standard deviation of 0.27. Finally, at 12 months, the range of leg lying scores ranged from 0 to 1, with a mean of 0.82 and a standard deviation of 0.38. Similarly, the leg standing measurements were assessed at different time points in the study population. The baseline leg standing scores ranged from 3 to 6, with a mean of 4.3 and a standard deviation of 0.72. At 1 month, the leg standing scores ranged from 2 to 4, with a mean of 3.3 and a standard deviation of 0.56. After 3 months, the leg standing scores ranged from 1 to 4, with a mean of 2.75 and a standard deviation of 0.59. At 6 months, the leg standing scores ranged from 1 to 2, with a mean of 1.82 and a standard deviation of 0.38. Finally, at 12 months, the leg standing scores ranged from 1 to 2, with a mean of 1.75 and a standard deviation of 0.44.The baseline for dyspareunia in the research sample varied between 4 and 8, with a mean value of 5.58 ± 0.93. The occurrence of dyspareunia one month later in the study group varied between 2 and 4, with a mean value of 2.78 ± 0.58. Similarly, the occurrence of dyspareunia three months later in the study population ranged from 1 to 3, with a mean value of 1.95 ± 0.45. Dyspareunia is a medical condition characterized by persistent or recurrent pain experienced during sexual After a period of 6 months, the range of dyspareunia prevalence in the study population was found to be between 1 and 3, with a mean value of 1.85 ± 0.48. After a period of 12 months, the range of values observed in the study population was between 1 and 2, with a mean value of 1.7 ± 0.46 (mean ± standard deviation).The baseline pain experienced during menstruation in the study group varied between 4 and 7, with a mean ± standard deviation (SD) of 5.3 ± 0.91. One month later, the pain experienced during menstruation in the study population ranged from 2 to 4, with a mean ± SD of 2.62 ± 0.59. After a period of 3 months, the range of pain experienced during menstruation in the study group was found to be between 2 and 3, with a mean value of 2.38 ± 0.49 (mean ± standard deviation). This pain is specifically associated with the menstrual cycle. After a period of 6 months, the range of values observed in the study population varied from 1 to 3, with a mean value of 1.98 and a standard deviation of 0.42. The research population experienced pain during menstruation 12 months later, with a range of 1 to 3 on a scale. The mean pain score was 1.8 ± 0.46.The research population had a 62.50% improvement rate, with 25 individuals experiencing a better state. The study population consisted of 33 patients, representing 82.50% of the total, who did not experience any complications.
Based on the results obtained, it is recommended that further investigations be conducted using a bigger sample size and on a broader scale in order to underscore the validity of our conclusions.